Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

Widening demographic gaps in CAR-T therapy utilization for multiple myeloma in the United States

Bone Marrow Transplantation volume 58, pages 1400–1402 (2023)Cite this article

Subjects

Chimeric Antigen Receptor T-cell (CAR-T) therapy is a promising anti-multiple myeloma (MM) treatment option. Based on results from clinical trials of patients in relapsed/refractory MM [1, 2] two CAR-T therapies have been FDA-approved: idecabtagene vicleucel in 3/2021 and ciltacabtagene autoleucel in 2/2022. Evidence suggests that novel therapies often result in socioeconomic and racial disparities in access [3]. With the promise of superior MM control with CAR-T therapy, it is important to ensure equitable access to the treatment for all patients.

A small but growing body of literature suggests racial disparities in the utilization of CAR-T [4, 5]. As of December 2022, Public Law 117–328 was enacted by the US Federal Drug Administration requiring clinical trials to include diversity action plans in order to ensure better representation of the national population. However, once a drug is approved, there are few, if any, mechanisms in place to enforce equitable access. We sought to explore differences in CAR-T therapy utilization by age, sex, race, and ethnicity using a large and representative dataset.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Berdeja JG, Madduri D, Usmani SZ, Jakubowiak A, Agha M, Cohen AD, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet. 2021;398:314–24.

    Article  CAS  PubMed  Google Scholar 

  2. Munshi NC, Anderson LD Jr. Shah N, Madduri D, Berdeja J, Lonial S, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384:705–16.

    Article  CAS  PubMed  Google Scholar 

  3. Blue B. Socioeconomic and Racial Disparity in Chimeric antigen receptor T cell (CART)Therapy Access. Transpl Cell Ther. 2022;28:345–6.

    Article  Google Scholar 

  4. Ahmed N, Shahzad M, Shippey E, Bansal R, Mushtaq MU, Mahmoudjafari Z, et al. Socioeconomic and racial disparity in chimeric antigen receptor T cell therapy access. Transpl Cell Ther. 2022;28:358–64.

    Article  Google Scholar 

  5. Alqazaqi R, Schinke C, Thanendrarajan S, Zangari M, Shaughnessy J Jr. Zhan F, et al. Geographic and racial disparities in access to chimeric antigen receptor-T cells and bispecific antibodies trials for multiple myeloma. JAMA Netw Open. 2022;5:e2228877.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Marinac CR, Ghobrial IM, Birmann BM, Soiffer J, Rebbeck TR. Dissecting racial disparities in multiple myeloma. Blood Cancer J. 2020;10:19.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Beech BM, Ford C, Thorpe RJ Jr. Bruce MA, Norris KC. Poverty, racism, and the public health crisis in America. Front Public Health. 2021;9:699049.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Munshi PN, Vesole DH, St Martin A, Davila O, Kumar S, Qazilbash M, et al. Outcomes of upfront autologous hematopoietic cell transplantation in patients with multiple myeloma who are 75 years old or older. Cancer. 2021;127:4233–9.

    Article  PubMed  Google Scholar 

  9. Costa LJ, Huang JX, Hari PN. Disparities in utilization of autologous hematopoietic cell transplantation for treatment of multiple myeloma. Biol Blood Marrow Transplant : J Am Soc Blood Marrow Transplant. 2015;21:701–6.

    Article  Google Scholar 

  10. Schriber JR, Hari PN, Ahn KW, Fei M, Costa LJ, Kharfan-Dabaja MA, et al. Hispanics have the lowest stem cell transplant utilization rate for autologous hematopoietic cell transplantation for multiple myeloma in the United States: a CIBMTR report. Cancer. 2017;123:3141–9.

    Article  CAS  PubMed  Google Scholar 

  11. Shouse G, Danilov AV, Artz A. CAR T-cell therapy in the older person: indications and risks. Curr Oncol Rep. 2022;24:1189–99.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

Research reported in this publication was supported by a grant funded by the MCW Collaborative for Healthcare Delivery Science (AD). The content is solely the responsibility of the authors and does not necessarily represent the official views of the funder. The TriNetX data reported here have been supplied by the Medical College of Wisconsin Clinical Research Data Warehouse. The interpretation and reporting of these data are the responsibility of the author(s) and in no way should be seen as an official policy of or interpretation by the Medical College of Wisconsin.

Author information

Authors and Affiliations

  1. Medical College of Wisconsin (MCW) Medical School, Milwaukee, WI, USA

    Mingqian Lin

  2. Division of Hematology/Oncology, Department of Medicine, MCW, Milwaukee, WI, USA

    Noel Estrada-Merly, Mary Eapen, Anthony E. Zamora, William R. Drobyski & Anita D’Souza

  3. Institute of Health and Safety, MCW, Milwaukee, WI, USA

    Liliana E. Pezzin

  4. MCW Pharmacy School, Milwaukee, WI, USA

    Aaron N. Winn

  5. ThedaCare Regional Cancer Center, Appleton, WI, USA

    Joyce Philip

  6. Division of Hematology/Oncology, Department of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, USA

    Carolina Schinke

  7. Department of Internal Medicine, University of Texas Southwestern, Dallas, TX, USA

    Larry D. Anderson Jr.

Authors
  1. Mingqian Lin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Noel Estrada-Merly
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mary Eapen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Anthony E. Zamora
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Liliana E. Pezzin
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Aaron N. Winn
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Joyce Philip
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Carolina Schinke
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. William R. Drobyski
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Larry D. Anderson Jr.
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Anita D’Souza
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

All authors contributed toward study design, analysis, review of findings, and manuscript writing.

Corresponding author

Correspondence to Anita D’Souza.

Ethics declarations

Competing interests

ML, NE, ME, LEP, ANW, JP, WD report no conflicts of interest relevant to this work. AEZ reports research support from PhenomeX not related to the data presented in the current study. CS reports Consulting/Advisory Board activity with Janssen and Pfizer. LA reports Consulting/Advisory Board activity with: Janssen, Celgene, BMS, Amgen, GSK, AbbVie, Beigene, Cellectar, Sanofi, Prothena; AD reports institutional research funding from Abbvie, Caelum, Janssen, Novartis, Prothena, Sanofi, Sorrento, TeneoBio, consulting/advisory board activity with BMS, Janssen, Pfizer, Prothena.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lin, M., Estrada-Merly, N., Eapen, M. et al. Widening demographic gaps in CAR-T therapy utilization for multiple myeloma in the United States. Bone Marrow Transplant 58, 1400–1402 (2023). https://doi.org/10.1038/s41409-023-02102-4

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41409-023-02102-4

Search

Advanced search

Quick links